Mindfulness-Based Cognitive Therapy in Advanced Prostate Cancer: A Randomized Controlled Trial.

Autor:	Chambers SK; Suzanne K. Chambers, Stefano Occhipinti, Melissa Legg, and David P. Smith, Griffith University, Gold Coast; Suzanne K. Chambers, Samantha Clutton, Melissa Legg, Cancer Council Queensland; Robert A. Gardiner, University of Queensland, Brisbane; Suzanne K. Chambers, University of Southern Queensland, Toowoomba, Queensland; Suzanne K. Chambers, Prostate Cancer Foundation of Australia; Suzanne K. Chambers, Stefano Occhipinti, Samantha Clutton, Melissa Legg, Martin Berry, Martin R. Stockler, Mark Frydenberg, Robert A. Gardiner, Ian D. Davis, and David P. Smith, Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Elizabeth Foley, Mind Potential; Martin R. Stockler, and David P. Smith, University of Sydney; David P. Smith, Cancer Council New South Wales, Sydney; Martin Berry, Central Coast Cancer Centre, Gosford; Martin R. Stockler, Concord Repatriation General Hospital, Concord, New South Wales; Suzanne K. Chambers, Robert A. Gardiner, Edith Cowan University, Perth, Western Australia; Mark Frydenberg, Monash Health; Mark Frydenberg, Ian D. Davis, Monash University; Ian D. Davis, Eastern Health, Melbourne, Victoria, Australia; and Stephen J. Lepore, Temple University, Philadelphia, PA., Occhipinti S; Suzanne K. Chambers, Stefano Occhipinti, Melissa Legg, and David P. Smith, Griffith University, Gold Coast; Suzanne K. Chambers, Samantha Clutton, Melissa Legg, Cancer Council Queensland; Robert A. Gardiner, University of Queensland, Brisbane; Suzanne K. Chambers, University of Southern Queensland, Toowoomba, Queensland; Suzanne K. Chambers, Prostate Cancer Foundation of Australia; Suzanne K. Chambers, Stefano Occhipinti, Samantha Clutton, Melissa Legg, Martin Berry, Martin R. Stockler, Mark Frydenberg, Robert A. Gardiner, Ian D. Davis, and David P. Smith, Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Elizabeth Foley, Mind Potential; Martin R. Stockler, and David P. Smith, University of Sydney; David P. Smith, Cancer Council New South Wales, Sydney; Martin Berry, Central Coast Cancer Centre, Gosford; Martin R. Stockler, Concord Repatriation General Hospital, Concord, New South Wales; Suzanne K. Chambers, Robert A. Gardiner, Edith Cowan University, Perth, Western Australia; Mark Frydenberg, Monash Health; Mark Frydenberg, Ian D. Davis, Monash University; Ian D. Davis, Eastern Health, Melbourne, Victoria, Australia; and Stephen J. Lepore, Temple University, Philadelphia, PA., Foley E; Suzanne K. Chambers, Stefano Occhipinti, Melissa Legg, and David P. Smith, Griffith University, Gold Coast; Suzanne K. Chambers, Samantha Clutton, Melissa Legg, Cancer Council Queensland; Robert A. Gardiner, University of Queensland, Brisbane; Suzanne K. Chambers, University of Southern Queensland, Toowoomba, Queensland; Suzanne K. Chambers, Prostate Cancer Foundation of Australia; Suzanne K. Chambers, Stefano Occhipinti, Samantha Clutton, Melissa Legg, Martin Berry, Martin R. Stockler, Mark Frydenberg, Robert A. Gardiner, Ian D. Davis, and David P. Smith, Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Elizabeth Foley, Mind Potential; Martin R. Stockler, and David P. Smith, University of Sydney; David P. Smith, Cancer Council New South Wales, Sydney; Martin Berry, Central Coast Cancer Centre, Gosford; Martin R. Stockler, Concord Repatriation General Hospital, Concord, New South Wales; Suzanne K. Chambers, Robert A. Gardiner, Edith Cowan University, Perth, Western Australia; Mark Frydenberg, Monash Health; Mark Frydenberg, Ian D. Davis, Monash University; Ian D. Davis, Eastern Health, Melbourne, Victoria, Australia; and Stephen J. Lepore, Temple University, Philadelphia, PA., Clutton S; Suzanne K. Chambers, Stefano Occhipinti, Melissa Legg, and David P. Smith, Griffith University, Gold Coast; Suzanne K. Chambers, Samantha Clutton, Melissa Legg, Cancer Council Queensland; Robert A. Gardiner, University of Queensland, Brisbane; Suzanne K. Chambers, University of Southern Queensland, Toowoomba, Queensland; Suzanne K. Chambers, Prostate Cancer Foundation of Australia; Suzanne K. Chambers, Stefano Occhipinti, Samantha Clutton, Melissa Legg, Martin Berry, Martin R. Stockler, Mark Frydenberg, Robert A. Gardiner, Ian D. Davis, and David P. Smith, Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Elizabeth Foley, Mind Potential; Martin R. Stockler, and David P. Smith, University of Sydney; David P. Smith, Cancer Council New South Wales, Sydney; Martin Berry, Central Coast Cancer Centre, Gosford; Martin R. Stockler, Concord Repatriation General Hospital, Concord, New South Wales; Suzanne K. Chambers, Robert A. Gardiner, Edith Cowan University, Perth, Western Australia; Mark Frydenberg, Monash Health; Mark Frydenberg, Ian D. Davis, Monash University; Ian D. Davis, Eastern Health, Melbourne, Victoria, Australia; and Stephen J. Lepore, Temple University, Philadelphia, PA., Legg M; Suzanne K. Chambers, Stefano Occhipinti, Melissa Legg, and David P. Smith, Griffith University, Gold Coast; Suzanne K. Chambers, Samantha Clutton, Melissa Legg, Cancer Council Queensland; Robert A. Gardiner, University of Queensland, Brisbane; Suzanne K. Chambers, University of Southern Queensland, Toowoomba, Queensland; Suzanne K. Chambers, Prostate Cancer Foundation of Australia; Suzanne K. Chambers, Stefano Occhipinti, Samantha Clutton, Melissa Legg, Martin Berry, Martin R. Stockler, Mark Frydenberg, Robert A. Gardiner, Ian D. Davis, and David P. Smith, Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Elizabeth Foley, Mind Potential; Martin R. Stockler, and David P. Smith, University of Sydney; David P. Smith, Cancer Council New South Wales, Sydney; Martin Berry, Central Coast Cancer Centre, Gosford; Martin R. Stockler, Concord Repatriation General Hospital, Concord, New South Wales; Suzanne K. Chambers, Robert A. Gardiner, Edith Cowan University, Perth, Western Australia; Mark Frydenberg, Monash Health; Mark Frydenberg, Ian D. Davis, Monash University; Ian D. Davis, Eastern Health, Melbourne, Victoria, Australia; and Stephen J. Lepore, Temple University, Philadelphia, PA., Berry M; Suzanne K. Chambers, Stefano Occhipinti, Melissa Legg, and David P. Smith, Griffith University, Gold Coast; Suzanne K. Chambers, Samantha Clutton, Melissa Legg, Cancer Council Queensland; Robert A. Gardiner, University of Queensland, Brisbane; Suzanne K. Chambers, University of Southern Queensland, Toowoomba, Queensland; Suzanne K. Chambers, Prostate Cancer Foundation of Australia; Suzanne K. Chambers, Stefano Occhipinti, Samantha Clutton, Melissa Legg, Martin Berry, Martin R. Stockler, Mark Frydenberg, Robert A. Gardiner, Ian D. Davis, and David P. Smith, Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Elizabeth Foley, Mind Potential; Martin R. Stockler, and David P. Smith, University of Sydney; David P. Smith, Cancer Council New South Wales, Sydney; Martin Berry, Central Coast Cancer Centre, Gosford; Martin R. Stockler, Concord Repatriation General Hospital, Concord, New South Wales; Suzanne K. Chambers, Robert A. Gardiner, Edith Cowan University, Perth, Western Australia; Mark Frydenberg, Monash Health; Mark Frydenberg, Ian D. Davis, Monash University; Ian D. Davis, Eastern Health, Melbourne, Victoria, Australia; and Stephen J. Lepore, Temple University, Philadelphia, PA., Stockler MR; Suzanne K. Chambers, Stefano Occhipinti, Melissa Legg, and David P. Smith, Griffith University, Gold Coast; Suzanne K. Chambers, Samantha Clutton, Melissa Legg, Cancer Council Queensland; Robert A. Gardiner, University of Queensland, Brisbane; Suzanne K. Chambers, University of Southern Queensland, Toowoomba, Queensland; Suzanne K. Chambers, Prostate Cancer Foundation of Australia; Suzanne K. Chambers, Stefano Occhipinti, Samantha Clutton, Melissa Legg, Martin Berry, Martin R. Stockler, Mark Frydenberg, Robert A. Gardiner, Ian D. Davis, and David P. Smith, Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Elizabeth Foley, Mind Potential; Martin R. Stockler, and David P. Smith, University of Sydney; David P. Smith, Cancer Council New South Wales, Sydney; Martin Berry, Central Coast Cancer Centre, Gosford; Martin R. Stockler, Concord Repatriation General Hospital, Concord, New South Wales; Suzanne K. Chambers, Robert A. Gardiner, Edith Cowan University, Perth, Western Australia; Mark Frydenberg, Monash Health; Mark Frydenberg, Ian D. Davis, Monash University; Ian D. Davis, Eastern Health, Melbourne, Victoria, Australia; and Stephen J. Lepore, Temple University, Philadelphia, PA., Frydenberg M; Suzanne K. Chambers, Stefano Occhipinti, Melissa Legg, and David P. Smith, Griffith University, Gold Coast; Suzanne K. Chambers, Samantha Clutton, Melissa Legg, Cancer Council Queensland; Robert A. Gardiner, University of Queensland, Brisbane; Suzanne K. Chambers, University of Southern Queensland, Toowoomba, Queensland; Suzanne K. Chambers, Prostate Cancer Foundation of Australia; Suzanne K. Chambers, Stefano Occhipinti, Samantha Clutton, Melissa Legg, Martin Berry, Martin R. Stockler, Mark Frydenberg, Robert A. Gardiner, Ian D. Davis, and David P. Smith, Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Elizabeth Foley, Mind Potential; Martin R. Stockler, and David P. Smith, University of Sydney; David P. Smith, Cancer Council New South Wales, Sydney; Martin Berry, Central Coast Cancer Centre, Gosford; Martin R. Stockler, Concord Repatriation General Hospital, Concord, New South Wales; Suzanne K. Chambers, Robert A. Gardiner, Edith Cowan University, Perth, Western Australia; Mark Frydenberg, Monash Health; Mark Frydenberg, Ian D. Davis, Monash University; Ian D. Davis, Eastern Health, Melbourne, Victoria, Australia; and Stephen J. Lepore, Temple University, Philadelphia, PA., Gardiner RA; Suzanne K. Chambers, Stefano Occhipinti, Melissa Legg, and David P. Smith, Griffith University, Gold Coast; Suzanne K. Chambers, Samantha Clutton, Melissa Legg, Cancer Council Queensland; Robert A. Gardiner, University of Queensland, Brisbane; Suzanne K. Chambers, University of Southern Queensland, Toowoomba, Queensland; Suzanne K. Chambers, Prostate Cancer Foundation of Australia; Suzanne K. Chambers, Stefano Occhipinti, Samantha Clutton, Melissa Legg, Martin Berry, Martin R. Stockler, Mark Frydenberg, Robert A. Gardiner, Ian D. Davis, and David P. Smith, Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Elizabeth Foley, Mind Potential; Martin R. Stockler, and David P. Smith, University of Sydney; David P. Smith, Cancer Council New South Wales, Sydney; Martin Berry, Central Coast Cancer Centre, Gosford; Martin R. Stockler, Concord Repatriation General Hospital, Concord, New South Wales; Suzanne K. Chambers, Robert A. Gardiner, Edith Cowan University, Perth, Western Australia; Mark Frydenberg, Monash Health; Mark Frydenberg, Ian D. Davis, Monash University; Ian D. Davis, Eastern Health, Melbourne, Victoria, Australia; and Stephen J. Lepore, Temple University, Philadelphia, PA., Lepore SJ; Suzanne K. Chambers, Stefano Occhipinti, Melissa Legg, and David P. Smith, Griffith University, Gold Coast; Suzanne K. Chambers, Samantha Clutton, Melissa Legg, Cancer Council Queensland; Robert A. Gardiner, University of Queensland, Brisbane; Suzanne K. Chambers, University of Southern Queensland, Toowoomba, Queensland; Suzanne K. Chambers, Prostate Cancer Foundation of Australia; Suzanne K. Chambers, Stefano Occhipinti, Samantha Clutton, Melissa Legg, Martin Berry, Martin R. Stockler, Mark Frydenberg, Robert A. Gardiner, Ian D. Davis, and David P. Smith, Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Elizabeth Foley, Mind Potential; Martin R. Stockler, and David P. Smith, University of Sydney; David P. Smith, Cancer Council New South Wales, Sydney; Martin Berry, Central Coast Cancer Centre, Gosford; Martin R. Stockler, Concord Repatriation General Hospital, Concord, New South Wales; Suzanne K. Chambers, Robert A. Gardiner, Edith Cowan University, Perth, Western Australia; Mark Frydenberg, Monash Health; Mark Frydenberg, Ian D. Davis, Monash University; Ian D. Davis, Eastern Health, Melbourne, Victoria, Australia; and Stephen J. Lepore, Temple University, Philadelphia, PA., Davis ID; Suzanne K. Chambers, Stefano Occhipinti, Melissa Legg, and David P. Smith, Griffith University, Gold Coast; Suzanne K. Chambers, Samantha Clutton, Melissa Legg, Cancer Council Queensland; Robert A. Gardiner, University of Queensland, Brisbane; Suzanne K. Chambers, University of Southern Queensland, Toowoomba, Queensland; Suzanne K. Chambers, Prostate Cancer Foundation of Australia; Suzanne K. Chambers, Stefano Occhipinti, Samantha Clutton, Melissa Legg, Martin Berry, Martin R. Stockler, Mark Frydenberg, Robert A. Gardiner, Ian D. Davis, and David P. Smith, Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Elizabeth Foley, Mind Potential; Martin R. Stockler, and David P. Smith, University of Sydney; David P. Smith, Cancer Council New South Wales, Sydney; Martin Berry, Central Coast Cancer Centre, Gosford; Martin R. Stockler, Concord Repatriation General Hospital, Concord, New South Wales; Suzanne K. Chambers, Robert A. Gardiner, Edith Cowan University, Perth, Western Australia; Mark Frydenberg, Monash Health; Mark Frydenberg, Ian D. Davis, Monash University; Ian D. Davis, Eastern Health, Melbourne, Victoria, Australia; and Stephen J. Lepore, Temple University, Philadelphia, PA., Smith DP; Suzanne K. Chambers, Stefano Occhipinti, Melissa Legg, and David P. Smith, Griffith University, Gold Coast; Suzanne K. Chambers, Samantha Clutton, Melissa Legg, Cancer Council Queensland; Robert A. Gardiner, University of Queensland, Brisbane; Suzanne K. Chambers, University of Southern Queensland, Toowoomba, Queensland; Suzanne K. Chambers, Prostate Cancer Foundation of Australia; Suzanne K. Chambers, Stefano Occhipinti, Samantha Clutton, Melissa Legg, Martin Berry, Martin R. Stockler, Mark Frydenberg, Robert A. Gardiner, Ian D. Davis, and David P. Smith, Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Elizabeth Foley, Mind Potential; Martin R. Stockler, and David P. Smith, University of Sydney; David P. Smith, Cancer Council New South Wales, Sydney; Martin Berry, Central Coast Cancer Centre, Gosford; Martin R. Stockler, Concord Repatriation General Hospital, Concord, New South Wales; Suzanne K. Chambers, Robert A. Gardiner, Edith Cowan University, Perth, Western Australia; Mark Frydenberg, Monash Health; Mark Frydenberg, Ian D. Davis, Monash University; Ian D. Davis, Eastern Health, Melbourne, Victoria, Australia; and Stephen J. Lepore, Temple University, Philadelphia, PA.
Jazyk:	angličtina
Zdroj:	Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2017 Jan 20; Vol. 35 (3), pp. 291-297. Date of Electronic Publication: 2016 Nov 21.
DOI:	10.1200/JCO.2016.68.8788
Abstrakt:	Purpose Advanced prostate cancer (PC) is associated with substantial psychosocial morbidity. We sought to determine whether mindfulness-based cognitive therapy (MBCT) reduces distress in men with advanced PC. Methods Men with advanced PC (proven metastatic and/or castration-resistant biochemical progression) were randomly assigned to an 8-week, group-based MBCT intervention delivered by telephone (n = 94) or to minimally enhanced usual care (n = 95). Primary intervention outcomes were psychological distress, cancer-specific distress, and prostate-specific antigen anxiety. Mindfulness skills were assessed as potential mediators of effect. Participants were assessed at baseline and were followed up at 3, 6, and 9 months. Main statistical analyses were conducted on the basis of intention to treat. Results Fourteen MBCT groups were conducted in the intervention arm. Facilitator adherence ratings were high (> 93%). Using random-effects mixed-regression models, intention-to-treat analyses indicated no significant changes in intervention outcomes or in engagement with mindfulness for men in MBCT compared with those receiving minimally enhanced usual care. Per-protocol analyses also found no differences between arms in outcomes or engagement, with the exception of the mindfulness skill of observing, which increased over time for men in MBCT compared with usual care ( P = .032). Conclusion MBCT in this format was not more effective than minimally enhanced usual care in reducing distress in men with advanced PC. Future intervention research for these men should consider approaches that map more closely to masculinity.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu